Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

BTH, I agree with your contention that the subset data is likely going to show significant benefit in a broad range of STS types but only marginal benefit in others, I also believe this was anticipated and, consequently, a review of pre-defined groupings was built into the trial from the very beginning. However, given the lack of alternative treatments and the positioning of rida as a maintenance therapy, I'd be very surprised if rida did not get approved based on the top-line results alone.